Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - Riot Blockchain, Inc.ex99x1.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of earliest event reported)   October 26, 2010
 
AspenBio Pharma, Inc.
(Exact name of Registrant as specified in its charter)
 
Colorado
 
001-33675
 
84-155338
(State or other jurisdiction of
incorporation)
 
(Commission File Number)
 
(I.R.S. Employer Identification No.)
 
 
1585 South Perry Street
Castle Rock, Colorado
 
80104
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code  (303) 794-2000
 
 
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
 
 
 

 

Item 8.01.  Other Events.
 
On October 26, 2010, AspenBio Pharma, Inc. (the “Company”) issued a press release titled — “AspenBio Advances AppyScore™ Cassette-Based Test and Adds Regulatory and Sales and Marketing Expertise.” The press release is filed as Exhibit 99.1 to this Form 8-K.

 
Item 9.01.  Financial Statements and Exhibits.
 
(d)           Exhibits
 
Exhibits
 
99.1
Press release, dated October 26, 2010, issued by AspenBio Pharma, Inc. titled “AspenBio Advances AppyScore™ Cassette-Based Test and Adds Regulatory and Sales and Marketing Expertise.”
 
 
 
 
 
 
 

 
 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized
 
         
     
   
AspenBio Pharma, Inc.
         (Registrant)
 
 
 
Date:  October 26, 2010 
By:  
 /s/ Jeffrey G. McGonegal  
 
    Name:  Jeffrey G. McGonegal  
    Title:    Chief Financial Officer